

Dose-Survival in SVZ and SGZ of patients with Glioma

Irradiation of the Subventricular Zone and Subgranular Zone: an Atlas-based analysis on Overall Survival in High- and Low-Grade Glioma Patients

Danique E. Bruil B.Sc.¹, Szabolcs David Ph.D.¹, Steven H.J Nagtegaal M.D.¹, Sophia F.A.M de Sonnaville M.D.², Joost J.C. Verhoeff M.D. Ph.D.¹

¹Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands

HP Q 00.3.11

PO box 85500

3508 GA

Utrecht, the Netherlands

²Department of Neurosurgery, University Medical Center Utrecht, The Netherlands

HP G 03.129

PO box 85500

3508 GA

Utrecht, the Netherlands

Corresponding author:

Joost J.C. Verhoeff M.D. Ph.D.

HP Q 00.3.11

PO box 85500

3508 GA

Utrecht, the Netherlands

j.j.c.verhoeff-10@umcutrecht.nl

Funding

None.

Conflict of Interest

None.

Authorship

Concept: DEB, SD, SHJN, JJCV

Writing: DEB, SD, SHJN, SFAMdS, JJCV

Data processing: DEB, SD

Statistics: DEB, SHJN

Revision: SD, SHJN, SFAMdS, JJCV

All authors have seen and approved the manuscript.

Manuscript word count, including abstract, text, references and figure legends: 5849

Dose-Survival in SVZ and SGZ of patients with Glioma

1 **Abstract**

2 Background: Neural stem cells in the subventricular- (SVZ) and subgranular zone (SGZ) are hypothesized
3 to support growth of glioma. Therefore, irradiation of the SVZ and SGZ might reduce tumor growth and
4 might improve overall survival (OS). However, it may also inhibit the repair capacity of brain tissue. The
5 aim of this retrospective cohort study is to assess the impact of SVZ and SGZ radiotherapy doses on OS of
6 patients with high-grade (HGG) or low-grade (LGG) glioma.

7 Methods: We included 273 glioma patients who received radiotherapy. We created an SVZ atlas, shared
8 openly with this work, while SGZ labels were taken from the CoBRA atlas. Next, SVZ and SGZ regions were
9 automatically delineated on T1 MR-images. Dose and OS correlations were investigated with Cox
10 regression and Kaplan-Meier analysis.

11 Results: Cox regression analyses showed significant hazard ratios for SVZ dose (univariate: 1.029/Gy,
12 $p < 0.001$; multivariate: 1.103/Gy, $p = 0.002$) and SGZ dose (univariate: 1.023/Gy, $p < 0.001$; multivariate:
13 1.055/Gy, $p < 0.001$) in HGG patients. Kaplan-Meier analysis showed significant correlations between OS
14 and high/low dose groups for HGG patients (SVZ: respectively 10.7 months (>30.33 Gy) vs 14.0 months
15 (<30.33 Gy) median OS, $p = 0.011$; SGZ: respectively 10.7 months (>29.11 Gy) vs 15.5 months (<29.11 Gy)
16 median OS, $p < 0.001$). No correlations between dose and OS were not found for LGG patients.

17 Conclusion: Irradiation doses on neurogenic areas correlate negatively with OS in patients with HGG.
18 Whether sparing of the SVZ and SGZ during radiotherapy improves OS, should be subject of prospective
19 studies.

Dose-Survival in SVZ and SGZ of patients with Glioma

20 **Keywords**

21 Radiotherapy; Glioma; Subventricular Zone; Subgranular Zone; Overall Survival

22

23 **Key Points**

- 24 • Neural stem cells in the SVZ and SGZ are hypothesized to support growth of glioma.
- 25 • Higher radiation doses on the SVZ and SGZ correlate with lower OS in HGG patients.
- 26 • Avoidance of neurogenic niches should be considered to improve OS of HGG patients.

27

28 **Importance of Study**

29 Survival rates and quality of life of patients with glioma are still suboptimal, therefore improvement of
30 radiation treatment planning and delivery is required. The SVZ and SGZ of the adult human brain are a
31 source of brain tissue repair but may also be the source of glioma growth enhancement. By investigating
32 the effects of radiotherapy on SVZ and SGZ, we gain insight into associations between tumor progression
33 and survival. We included 273 adult patients with high- and low- grade glioma who received radiation
34 treatment. We found that irradiation doses on neurogenic areas correlate with lower OS in patients with
35 HGG. Avoidance of SVZ and SGZ should be considered to improve OS. These study results will contribute
36 to optimization of brain tumor radiotherapy, focused on increasing OS. In order to facilitate future
37 research into the role of the SVZ, we also provide stereotaxic standard space atlas labels for SVZ and SGZ.

38

39 **Abbreviations**

40 CAT = Computational Anatomy Toolbox; CI = Confidence interval; CT = Chemotherapy; CTV = Clinical target
41 volume; DG = Dentate gyrus; FH = Frontal horn; GTV = Gross tumor volume; HGG = High-grade glioma;
42 HPC = hippocampus; HR = Hazard ratio; IDH = Isocitrate dehydrogenase; IQR = Interquartile range; KPS =
43 Karnofsky Performance Score; LGG = Low-grade glioma; MGMT = O6-Methylguanine methyltransferase;

Dose-Survival in SVZ and SGZ of patients with Glioma

- 44 NSC = Neural stem cell; OH = Occipital horn; OS = Overall survival; PFS = Progression-free survival; PTV =
- 45 planning target volume; RT = radiotherapy; SGZ = Subgranular zone; SPM = Statistical Parametric Mapping;
- 46 SVZ = Subventricular zone; TH = Temporal horn; TSE = Turbo Spin Echo; VBG = Virtual Brain Grafting

Dose-Survival in SVZ and SGZ of patients with Glioma

47 **Introduction**

48 Glioma is the most common primary brain tumor, and it consists of glial cells which normally support the
49 functioning of nerve cells.^{1,2} Survival rates in glioma patients depend on several clinical factors, such as
50 tumor progression and WHO grade. Patients with low-grade glioma (LGG; WHO grade I and II) have a
51 median survival of 5.6 to 11.6 years, while patients with high-grade glioma (HGG; WHO grade III and IV)
52 have a median survival of 14 months to 3.5 years and almost always develop recurrences.³ Current clinical
53 management consists of a combination of different concurrent and consecutive treatments: tumor
54 resection, radiotherapy (RT) and chemotherapy (CT), to reduce tumor size and inhibit progression.^{2,4} To
55 increase survival rate and quality of life of patients with glioma, it is essential to further improve current
56 treatment modalities and investigate the effects of modulating radiation dose to presumed tumor
57 supporting brain regions.

58 Recent studies have shown that the growth of glioma might be supported by cells originating from the
59 subventricular zone (SVZ), providing the tumor with neural stem cells (NSCs) and progenitor cells.⁵⁻⁷ Lee
60 et al. have shown that neural tissue of HGG patients have NSCs in the SVZ that contain similar driver
61 mutations as their matching glioma, which can migrate and result in progression of HGG.⁵ Others found
62 that anatomical contact of the tumor with the SVZ correlates with lower survival rates in both HGG and
63 LGG glioma, independent of other prognostic factors.⁶⁻⁸ The SVZ, which is located along the lateral wall of
64 the ventricles, is one of the neurogenic niches in the brain, next to the subgranular zone (SGZ) in the
65 dentate gyrus (DG) of the hippocampus (HPC).⁹⁻¹¹ The main role of these niches is neurogenesis, through
66 the generation of multipotent NSCs from the embryonic stage throughout adulthood.⁹⁻¹¹ The SVZ has
67 been shown to play a role in tissue repair and prevention of neurodegenerative diseases,^{12,13} while the
68 SGZ generates NSCs that are involved in pathways of learning and memory.^{9,14} In contrast to NSCs from
69 the SVZ, NSCs in the SGZ are thought unlikely to support glioma development.¹⁵ It has been shown that
70 irradiation of the SGZ can result in cognitive decline in patients with central nervous system

Dose-Survival in SVZ and SGZ of patients with Glioma

71 malignancies¹⁶, which is associated with lower overall survival (OS).^{17,18} Studies which investigated
72 irradiation of the SVZ on the other hand, showed that HGG patients who received a high irradiation dose
73 (>40 Gy) on the SVZ have improved OS and Progression-free Survival (PFS), compared to patients that
74 receive a low irradiation dose on the SVZ.¹⁹⁻²³ These findings suggest that for HGG, the SVZ should be
75 targeted with high dose during RT to decrease tumor regrowth, while the SGZ might need to be spared to
76 prevent cognitive decline. Contradictory, irradiating the SVZ and therefore damaging its repair capacity
77 for normal brain tissue as well, may lead to opposing effects on OS as previous studies show.
78 The goal of this retrospective cohort study is to determine whether irradiation of the SVZ and SGZ in
79 patients with HGG and LGG will increase survival, by comparing OS of these cohorts to irradiation doses
80 applied to the SVZ and SGZ. By investigating the effects of radiotherapy to SVZ and SGZ in glioma patients,
81 clues for further treatment optimization in the neuro-oncology field may be provided.

Dose-Survival in SVZ and SGZ of patients with Glioma

82 **Materials and Methods**

83 Patient selection and data collection

84 Patients diagnosed with glioma who received RT between November 2014 and July 2020 at the
85 Department of Radiation Oncology of the UMC Utrecht were retrospectively selected. T1-weighted MR
86 images without contrast enhancement and CT images with mapped radiation dose were collected for
87 every patient. Gross tumor volume (GTV), clinical target volume (CTV) and planning target volume (PTV)
88 were defined by a radiation oncologist as part of routine clinical care. Next, we collected clinical prognostic
89 data, which includes age, sex, Karnofsky Performance Score (KPS), date of last follow-up, date of death,
90 RT start date, survival time, RT dose, RT fractions, total intracranial volume calculated from T1 scans,
91 (extent of) resection, (type of) CT and distance between SVZ or the HPC and GTV. The dataset also includes
92 WHO grade and molecular markers of prognosis: isocitrate dehydrogenase (IDH)-mutation status, O6-
93 methylguanine methyltransferase (MGMT) methylation status and 1P/19Q-codeletion status.^{24–27}
94 Inclusion criteria for constructing the dataset were: patients diagnosed with glioma, receiving cranial RT
95 between November 2014 and July 2020, age ≥ 18 years, and accessible planning and dosimetry data.
96 Exclusion criteria were: rare cancer type or disease, re-irradiation and whole-brain radiotherapy. Patients
97 with WHO-grade I/II and WHO-grade III/IV glioma were investigated separately as LGG and HGG cohorts,
98 respectively. Informed consent for this retrospective study was waived by our institutional review board
99 (#18/274).

100

101 Image Acquisition

102 MR images were acquired on a 3T Philips Ingenia scanner (Philips Healthcare, Best, The Netherlands) as
103 part of routine clinical care. T1-weighted MR images were acquired with a 3D turbo-spin echo (TSE)
104 sequence without contrast enhancement, with the following parameters: TR = 8.1 ms, TE = 3.7 ms, flip
105 angle = 8°, 213 continuous axial slices without gap, matrix: 207 x 289, voxel resolution 1 × 0.96 × 0.96 mm.

Dose-Survival in SVZ and SGZ of patients with Glioma

106 The planning CT scans were acquired on a Brilliance Big bore scanner (Philips Medical Systems, Best, The
107 Netherlands), with a tube potential of 120 kVp, using a matrix size of 512×512 and $0.65 \times 0.65 \times 3.0$ mm
108 voxel size.

109

110 Image processing and segmentation

111 All imaging data was processed with FSL,²⁸ Statistical Parametric Mapping (SPM),²⁹ Computational
112 Anatomy Toolbox (CAT12)³⁰ and Virtual Brain Grafting (VBG).³¹ Image processing was done according to
113 our previously published criteria.³² More detailed methods can be found in **Supplementary Material**
114 **Appendix 1**. The SGZ masks were acquired via nonlinear registration of the Hippocampus and Subfields
115 CoBra atlas by Winterburn et al.³³ using the CAT12 toolbox.³⁰ Previously conducted studies acquired SVZ
116 labels via manual delineation with varying definitions. In order to facilitate the production and
117 reproducibility of similar research, we developed an SVZ atlas, defined in the symmetric $0.5 \times 0.5 \times 0.5$ mm³
118 MNI-ICBM 152 space (Montreal Neurological Institute-International Consortium for Brain Mapping
119 template created from 152 healthy brain).³⁴⁻³⁶ The atlas is substantiated by the neuro-anatomic
120 development of the SVZ and divided in 4 subregions by the supervision of a neuro-pathologist. **Figure 1**
121 shows a visual overview of the SVZ and its subregions, along with the HPC and its subregions, as well as
122 the fornix. Details on the defining process of the SVZ atlas are available in **Supplementary Material**
123 **Appendix 2**.

124

125 Statistical analyses

126 Data analysis was performed using IBM SPSS (for Windows, version 26.0.0.1). As mentioned before, the
127 primary outcome of this study was OS, defined as months after the first RT session until date of death or
128 last follow-up. Patients that were alive at time of their last follow-up, are censored at the follow-up date.

Dose-Survival in SVZ and SGZ of patients with Glioma

129 The relationship between the mean dose on neurogenic subregions and OS was examined using the Cox
130 Proportional Hazards model³⁷ and the Kaplan-Meier estimator³⁸. Cox Proportional Hazard models were
131 performed with the log partial likelihood ratio test, to calculate the hazard ratios. They were executed
132 both with and without correcting for the following prognostic factors: age, sex, KPS, total intracranial
133 volume, mutations, surgery-extent, CT, SVZ/GTV contact and HPC/GTV contact. For the Kaplan-Meier
134 analysis, patients were dichotomized in two groups based on the median of the mean dose for each
135 neurogenic structure. This resulted in a high-dose group (patients that received greater than the median
136 dose) and a low-dose group (patients that received lower than the median dose). Kaplan-Meier survival
137 curves were compared with the log-rank test. Significance was set at $p < 0.05$ and the confidence interval
138 (CI) was set at 95%. Moreover, Kaplan-Meier survival analysis was performed for GTV contact with the
139 SVZ or HPC, using the same methods as Berendsen et al., Liu et al. and Chiang et al.⁶⁻⁸

Dose-Survival in SVZ and SGZ of patients with Glioma

140 **Results**

141 Participants

142 From all 338 patients that received RT between November 2014 and July 2020, a subset of 273 patients
143 met the inclusion criteria and was selected for analysis. 32 patients were excluded due to re-irradiation
144 and 33 patients were excluded because one or more items were inaccessible or incomplete: planning,
145 delineation and/or dosimetry data. The remaining 273 patients were split up into HGG (n = 226) and LGG
146 patients (n = 47). As expected, the LGG patient group did not include WHO grade I pathologies, therefore
147 the cohort only contained WHO grade II glioma patients. The patient inclusion flowchart is shown in **Figure**
148 **2**. Baseline patient and treatment characteristics are shown in **Table 1**. In our cohort, the median OS from
149 onset of radiotherapy of HGG patients was 12.1 months and median OS of LGG patients was 35.2 months.
150 Median age of the HGG and LGG patients were 63 and 48 year, respectively. Prior to RT, all included
151 patients underwent any form of surgery (biopsy, debulking, resection), and most of them received a
152 partial resection.

153

154 Survival analysis

155 An overview of Cox regression analyses is shown in **Table 2**, for each patient cohort separately. For HGG
156 patients, univariate analysis resulted in a hazard ratio (HR) of 1.029 per Gy for the mean SVZ dose
157 ($p < 0.001$, [95% CI 1.013-1.046]) and 1.023 per Gy for the mean SGZ dose ($p < 0.001$, [95% CI 1.013-1.033]).
158 Multivariate analysis of HGG patient data corrected for age, sex, KPS, total intracranial volume, mutations,
159 CT, surgery-extent and SVZ/HPC contact resulted in a HR of 1.103 ($p = 0.002$, [95% CI 1.037-1.173]) and
160 1.055 ($p < 0.001$, [95% CI 1.027-1.083]) for the SVZ and SGZ, respectively. Dose on HPC, the occipital horn
161 (OH) of SVZ and temporal horn (TH) of SVZ all showed significant results with an HR >1, while the frontal
162 horn (FH) and SVZ body do not show significant results (**Table 2**).

Dose-Survival in SVZ and SGZ of patients with Glioma

163 Univariate analysis for LGG patients resulted in a non-significant HR of 1.028 per Gy for mean SVZ dose (p
164 = 0.506, [95% CI 0.948-1.114]) and 1.034 per Gy for mean SGZ dose (p = 0.273, [95% CI 0.974-1.098]).
165 Multivariate analysis of LGG patient data could not be corrected for mutations, as patients with known
166 mutations were still alive at time of data collection. Therefore, we corrected for age, sex, KPS, total
167 intracranial volume, CT, surgery-extent and SVZ/HPC contact. This resulted in an HR of 1.113 (p = 0.189,
168 [95% CI 0.949-1.305]) and 1.038 (p = 0.413, [95% CI 0.950-1.134]) for mean SVZ and SGZ doses,
169 respectively. Both univariate and multivariate Cox regression analysis did not result in significant
170 outcomes for any neurogenic regions in the LGG patient cohort (**Table 2**).

171
172 For Kaplan-Meier analysis, the median of the mean irradiation dose on each neurogenic subregion of the
173 entire glioma patient cohort (HGG + LGG patients) was used as cut-off value for low- and high-dose group
174 divisions (**Table 3**). For the SVZ, this was 30.33 Gy and for the SGZ 29.11 Gy.

175 HGG patients whose SVZ received high mean SVZ dose showed a significant difference of 3.3 months
176 shorter median OS, compared to patients who received low mean SVZ dose (10.7 months [95% CI 8.6-
177 12.8] vs 14.0 months [95% CI 11.6-16.3] median OS, p = 0.011). In case of the SGZ, HGG patients who
178 received high mean SGZ dose showed a significant decrease of 4.8 months in median OS, compared to
179 patients who received low mean SGZ dose (10.7 months [95% CI 8.8-12.7] vs 15.5 months [95% CI 12.5-
180 18.5] median OS, p <0.001).

181 Because the LGG cohort did not reach the proportion of 0.5 survival, median survival estimates could not
182 be calculated and therefore only mean survival estimates are given. The corresponding Kaplan-Meier
183 estimates and curves of SVZ and SGZ doses of both cohorts are shown in **Table 3** and **Figure 3**.

184 For ipsilateral and contralateral SVZ and SGZ doses, LGG patients did not show any significant OS
185 correlations. HGG patients whose ipsilateral SGZ received high mean ipsilateral SGZ dose (>45.03 Gy),
186 showed a significant difference of 4.8 months shorter OS, compared to patients who received low mean

Dose-Survival in SVZ and SGZ of patients with Glioma

187 ipsilateral SGZ dose (10.7 months [95% CI 8.1-12.5] vs 15.5 months [95% CI 12.5-18.5] median OS, $p =$
188 0.002). HGG patients whose contralateral SGZ received high mean contralateral SGZ dose (>12.54 Gy),
189 showed a significant decrease of 5.2 months in OS, compared to patients who received low median
190 contralateral SGZ dose (10.6 months [95% CI 9.0-12.3] vs 15.8 months [95% CI 13.1-18.6] median OS, $p =$
191 0.001). HGG patients whose ipsilateral SVZ received high mean ipsilateral SVZ dose (>39.41 Gy), showed
192 a significant decrease of 2.3 months in OS, compared to patients who received a low mean ipsilateral SVZ
193 dose (11.5 months [95% CI 9.7-13.4] vs 13.8 months [95% CI 11.6-16.0] median OS, $p = 0.035$).
194 HGG patients who had SVZ involvement in the GTV area had a median estimate of 4.3 months less survival
195 compared to patients who do not have contact of the GTV with the SVZ (11.4 months [95% CI 9.7-13.1] vs
196 15.7 months [95% CI 13.5-17.9] median OS, $p < 0.008$). Analyses of SVZ involvement in LGG patients did
197 not result in significant outcomes. We also did not find correlations between HPC contact with GTV and
198 OS, for both HGG and LGG patients.
199 More details and Kaplan-Meier curves of SVZ/HPC – tumor involvement, ipsilateral and contralateral dose
200 analysis and analysis of other neurogenic subregion doses are available in **Supplementary material**
201 **Appendix 3**.

Dose-Survival in SVZ and SGZ of patients with Glioma

202 **Discussion**

203 In this retrospective cohort study, we have tested whether contact between GTV and neurogenic niches
204 and/or irradiation dose to neurogenic niches in the adult human brain are associated with higher OS of
205 patients with HGG and LGG. Neurogenic stem cell areas play a role in the maintenance of healthy brain
206 tissue and repair, but may also enhance tumor growth. The hypothesis is based on previous pre-clinical
207 and clinical research which showed that the SVZ might support the growth of LGG and HGG by providing
208 the tumor with NSCs.^{5-8,39} However, it remains controversial, as there is a limited number of previous
209 studies that in contrast report that irradiation of the SVZ decreases OS for patients with HGG.⁴⁰⁻⁴³ A
210 preclinical study by Achanta et al. reported a decrease of the proliferating cell marker Ki67 in a mouse
211 model when the SVZ was irradiated,⁴⁴ indicating a deteriorated repair capacity. Studies from Achari et al.
212 and Elicin et al. showed dismal effects on OS after high irradiation doses on NSC niches of patients with
213 glioblastoma (n = 61 and n = 60 respectively),^{40,43} as did Muracciole et al. and Hallaert et al. reported for
214 IDH-wild-type HGG patients (n = 50 and n = 137 respectively).^{41,42} Our study describes this negative
215 correlation between SVZ irradiation and OS in HGG patients as well, involving a large number of patients
216 (n = 226). HGG patients whose SVZ received high mean SVZ dose (>30.33 Gy), showed a significantly
217 decrease of 3.3 months in median OS, compared to patients who received low mean SVZ dose (<30.33
218 Gy). Besides, multivariate Cox regression analysis showed HR's of 1.103 and 1.055 per Gy increasing
219 irradiation doses on the SVZ and SGZ, respectively.

220
221 On the contrary, the majority of previous studies in this field shows higher survival rates of HGG patients
222 following irradiation of the SVZ.¹⁹⁻²³ The prospective study from Malik et al. involving 45 glioblastoma
223 patients showed improved survival when patients receive additional irradiation dose on NSC niches in the
224 ipsilateral hemisphere.⁴⁵ We have investigated ipsilateral and contralateral doses on neurogenic niches as
225 well. Our retrospective outcomes show again that additional irradiation dose on both ipsilateral SVZ or

Dose-Survival in SVZ and SGZ of patients with Glioma

226 SGZ is negatively correlated with OS in HGG patients, contradicting the prospective study from Malik et
227 al. Interestingly, when considering the outcomes of the FH dose in HGG patients, neither univariate or
228 multivariate Cox regression and Kaplan-Meier survival outcomes are significant. This may indicate that
229 the FH is an area where the tumor is located more often than in other SVZ areas, which can interfere with
230 the results. However, the incidence of tumor location in the patient population of this study is evenly
231 divided between the SVZ subregions, and is not more common in the FH. This may suggest that the SVZ is
232 not a homogeneous neurogenic region.

233 In contrast to the NSCs from the SVZ, previous research elucidated that NSCs in the SGZ of the HPC are
234 not likely to sustain glioma growth, and that irradiation of the HPC may even result in cognitive decline
235 and lower OS.¹⁵⁻¹⁸ These results are in line with our findings, where we show that HGG patients who
236 received a high mean SGZ dose (>29.11 Gy) show a significant decrease of 4.8 months in median OS,
237 compared to patients who received a low median SGZ dose (<29.11 Gy).

238 We investigated the effect of irradiation on the SVZ and SGZ in LGG patients as well. Both the univariate
239 and the multivariate analysis of LGG patients did not result in a significant correlation between irradiation
240 dose on neurogenic niches and OS for LGG patients. This may be due to the relatively small number of
241 patients in our study that were diagnosed with WHO grade II.

242
243 Furthermore, we show that SVZ contact to the GTV is associated with a 4.3 months lower median OS in
244 HGG patients compared to patients that do not have SVZ contact with the GTV, which is in line with
245 findings by Berendsen et al.⁶ However, we are aware that this may be misleading, as the SVZ is located
246 centrally in the brain and it is suggested that central tumor location itself is associated with worse OS.⁴⁶
247 We performed similar analyses for LGG patients as well, following methods of Chiang et al.⁸ and Liu et al.⁷
248 but we did not find a relation between SVZ contact with GTV and survival in this patient group. The
249 outcomes may be due to our LGG patient sample size which is less than half of the sample size used in the

Dose-Survival in SVZ and SGZ of patients with Glioma

250 study of Liu et al.⁷ Another consideration is the atypical division of WHO grades in high- and low-grade, as
251 Chiang et al.⁸ included WHO III patients as LGG patients and we included WHO III patients in the HGG
252 cohort.

253
254 The dismal survival outcomes by high dose irradiation of neurogenic niches can be explained by the
255 neurotoxic side-effects of irradiation outweighing the positive effects. Lower survival might be caused by
256 the damaging of NSCs in the SVZ and SGZ, leading to decreased repair capacity and results in enhanced
257 neurocognitive impairment, which again is associated with lower OS.¹⁸

258 The strength of our study is the high number of HGG patients included in our analyses in comparison with
259 previous studies, which may support the soundness of our results. Also, the patients that were included
260 received fairly homogeneous treatments, with typically surgery followed by chemoRT and adjuvant CT.

261 Another consideration is the lack of consensus in literature on the delineation of the SVZ, due to lack of
262 existing guidelines and/or caused by irregular manual delineations.⁴⁷ Previous research was performed
263 with different volumes and shapes for the SVZ, causing inconsistency in methodology among studies. In
264 this study, we derived delineations of the SVZ from the open access SVZ atlas in standard MNI space,
265 which now can be used in future research, enabling reproducibility. Moreover, for dichotomization in low
266 and high RT dose groups, there is no congruence in literature about a cut-off value for irradiation dose. In
267 addition to dichotomization in low and high RT dose groups for Kaplan-Meier analysis, we chose to include
268 irradiation doses as continuous variables in cox-regression analyses as well, to avoid bias between specific
269 subcategories.⁴⁸

270 Nevertheless, our study shows there is room for improvements as well. First, since we could not collect
271 clinical follow-up data other than death, PFS could not be examined. Besides, we did not assess cognitive
272 performance of the patients, since neuropsychological evaluation was not performed routinely. Another
273 limitation may be the effect of tumor location, because a tumor that is located near the SVZ or SGZ leads

Dose-Survival in SVZ and SGZ of patients with Glioma

274 to elevated irradiation doses on the SVZ or SGZ as well. As it is suggested that central tumor location is
275 associated with worse OS,⁴⁶ it may interfere with the results. Therefore, we are aware that we cannot
276 correct our outcomes for tumor location completely. Furthermore, the limited number of LGG patients in
277 our study has probably led to insignificant results on their survival analysis. Finally, our study is of
278 retrospective nature, which might have resulted in selection bias. To validate our results, prospective
279 investigations are required, where irradiation and sparing of the neurogenic niches have to be compared.

280

281 In conclusion, in this retrospective study we present an SVZ atlas, SVZ delineation guidelines, and results
282 from a large cohort of patients with HGG, that shows a statistically significant decrease in median OS with
283 additional increased irradiation dose on the SVZ and SGZ. This suggests that, to improve OS, these
284 neurogenic niches need to be avoided with radiotherapy in HGG patients. Modern radiotherapy planning
285 systems and treatment delivery options are available to implement this tomorrow in most of the clinics.
286 Nevertheless, prospective and randomized investigations in patients with glioma are required first to
287 confirm our findings. The SVZ atlas which we defined here, is available for further use openly.

Dose-Survival in SVZ and SGZ of patients with Glioma

288 **Funding**

289 None.

290

291 **Acknowledgements**

292 We would like to thank Dr. Angelika Mühlebner (Department of Pathology, UMC Utrecht) for her
293 contributions to the SVZ atlas.

294

295 **References**

- 296 1 Vescovi, Angelo L, Galli, Rossella and Reynolds, Brent A (2006) "Brain tumour stem cells." *Nature*
297 *Reviews Cancer*, 6(6), pp. 425–436.
- 298 2 Reijneveld, J C (2010) "Neuro-oncologie," in *Het Neurologie Formularium*, Springer, pp. 210–217.
- 299 3 Sizoo, E M, Reijneveld, J C, Lagerwaard, F J, Buter, J, et al. (2010) "Beloop en beleid bij vermoeden
300 van een laaggradig glioom." *Nederlands Tijdschrift voor Geneeskunde*, 154.
- 301 4 Stupp, Roger, Mason, Warren P, van den Bent, Martin J, Weller, Michael, et al. (2005)
302 "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma." *New England*
303 *journal of medicine*, 352(10), pp. 987–996.
- 304 5 Lee, Joo Ho, Lee, Jeong Eun, Kahng, Jee Ye, Kim, Se Hoon, et al. (2018) "Human glioblastoma
305 arises from subventricular zone cells with low-level driver mutations." *Nature*, 560(7717), pp.
306 243–247.
- 307 6 Berendsen, Sharon, van Bodegraven, Emma, Seute, Tatjana, Spliet, Wim G M, et al. (2019)
308 "Adverse prognosis of glioblastoma contacting the subventricular zone: Biological correlates."
309 *PloS one*, 14(10), p. e0222717.
- 310 7 Liu, Shuai, Wang, Yinyan, Fan, Xing, Ma, Jun, et al. (2016) "Anatomical Involvement of the
311 Subventricular Zone Predicts Poor Survival Outcome in Low-Grade Astrocytomas." *PLOS ONE*,
312 11(4), p. e0154539.
- 313 8 Chiang, Gloria C, Pisapia, David J, Liechty, Benjamin, Magge, Rajiv, et al. (2020) "The Prognostic
314 Value of MRI Subventricular Zone Involvement and Tumor Genetics in Lower Grade Gliomas."
315 *Journal of Neuroimaging*, 30(6), pp. 901–909.
- 316 9 Zhao, Chunmei, Deng, Wei and Gage, Fred H (2008) "Mechanisms and functional implications of
317 adult neurogenesis." *Cell*, 132(4), pp. 645–660.

Dose-Survival in SVZ and SGZ of patients with Glioma

- 318 10 Katsimpardi, Lida and Lledo, Pierre-Marie (2018) "Regulation of neurogenesis in the adult and
319 aging brain." *Current opinion in neurobiology*, 53, pp. 131–138.
- 320 11 Bond, Allison M, Ming, Guo-li and Song, Hongjun (2015) "Adult mammalian neural stem cells and
321 neurogenesis: five decades later." *Cell stem cell*, 17(4), pp. 385–395.
- 322 12 Richardson, R Mark, Sun, Dong and Bullock, M Ross (2007) "Neurogenesis after traumatic brain
323 injury." *Neurosurgery Clinics*, 18(1), pp. 169–181.
- 324 13 Curtis, Maurice A, Faull, Richard L M and Eriksson, Peter S (2007) "The effect of
325 neurodegenerative diseases on the subventricular zone." *Nature Reviews Neuroscience*, 8(9), pp.
326 712–723.
- 327 14 Deng, Wei, Aimone, James B and Gage, Fred H (2010) "New neurons and new memories: how
328 does adult hippocampal neurogenesis affect learning and memory?" *Nature reviews*
329 *neuroscience*, 11(5), pp. 339–350.
- 330 15 Mistry, Akshitkumar M, Dewan, Michael C, White-Dzuro, Gabrielle A, Brinson, Philip R, et al.
331 (2017) "Decreased survival in glioblastomas is specific to contact with the ventricular-
332 subventricular zone, not subgranular zone or corpus callosum." *Journal of neuro-oncology*,
333 132(2), pp. 341–349.
- 334 16 Gondi, Vinai, Tomé, Wolfgang A and Mehta, Minesh P (2010) "Why avoid the hippocampus? A
335 comprehensive review." *Radiotherapy and Oncology*, 97, pp. 370–376.
- 336 17 Taphoorn, Martin J.B. and Klein, Martin (2004) "Cognitive deficits in adult patients with brain
337 tumours." *Lancet Neurology*, 3(3), pp. 159–168.
- 338 18 Klein, M, Postma, T J, Taphoorn, M J B, Aaronson, N K, et al. (2003) "The prognostic value of
339 cognitive functioning in the survival of patients with high-grade glioma." *Neurology*, 61(12), pp.
340 1796–1798.
- 341 19 Darázs, Barbara, Ruskó, László, Végváry, Zoltán, Ferenczi, Lehel, et al. (2019) "Subventricular zone
342 volumetric and dosimetric changes during postoperative brain tumor irradiation and its impact
343 on overall survival." *Physica Medica*, 68, pp. 35–40.
- 344 20 Chen, Linda, Guerrero-Cazares, Hugo, Ye, Xiaobu, Ford, Eric, et al. (2013) "Increased
345 subventricular zone radiation dose correlates with survival in glioblastoma patients after gross
346 total resection." *International Journal of Radiation Oncology* Biology* Physics*, 86(4), pp. 616–
347 622.
- 348 21 Lee, Percy, Eppinga, Wietse, Lagerwaard, Frank, Cloughesy, Timothy, et al. (2013) "Evaluation of
349 high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis."
350 *International Journal of Radiation Oncology* Biology* Physics*, 86(4), pp. 609–615.

Dose-Survival in SVZ and SGZ of patients with Glioma

- 351 22 Evers, Patrick, Lee, Percy P, DeMarco, John, Agazaryan, Nzhde, et al. (2010) "Irradiation of the
352 potential cancer stem cell niches in the adult brain improves progression-free survival of patients
353 with malignant glioma." *BMC Cancer* 2010 10:1, 10(1), pp. 1–7.
- 354 23 Gupta, Tejpal, Nair, Vimoj, Paul, Siji Nojin, Kannan, Sadhana, et al. (2012) "Can irradiation of
355 potential cancer stem-cell niche in the subventricular zone influence survival in patients with
356 newly diagnosed glioblastoma?" *Journal of Neuro-Oncology* 2012 109:1, 109(1), pp. 195–203.
- 357 24 Prognostik, Düflük Evreli Gliomlarda (2008) "Efficacy of prognostic factors on survival in patients
358 with low grade glioma." *Turkish neurosurgery*, 18(4), pp. 336–344.
- 359 25 Thakkar, Jigisha P, Dolecek, Therese A, Horbinski, Craig, Ostrom, Quinn T, et al. (2014)
360 "Epidemiologic and molecular prognostic review of glioblastoma." *Cancer Epidemiology and
361 Prevention Biomarkers*, 23(10), pp. 1985–1996.
- 362 26 Zhao, Ye-Yu, Chen, Si-Hai, Hao, Zheng, Zhu, Hua-Xin, et al. (2019) "A nomogram for predicting
363 individual prognosis of patients with low-grade glioma." *World neurosurgery*, 130, pp. e605–
364 e612.
- 365 27 Ducray, François, Idbaih, Ahmed, Wang, Xiao-Wei, Cheneau, Caroline, et al. (2011) "Predictive
366 and prognostic factors for gliomas." *Expert review of anticancer therapy*, 11(5), pp. 781–789.
- 367 28 Jenkinson, Mark, Beckmann, Christian F., Behrens, Timothy E.J., Woolrich, Mark W. and Smith,
368 Stephen M. (2012) "FSL." *NeuroImage*, 62(2), pp. 782–790.
- 369 29 Penny, William D, Friston, Karl J, Ashburner, John T, Kiebel, Stefan J and Nichols, Thomas E (2011)
370 *Statistical parametric mapping: the analysis of functional brain images*, Elsevier.
- 371 30 Gaser, C, Hbm, R Dahnke - and 2016, undefined (n.d.) "CAT-a computational anatomy toolbox for
372 the analysis of structural MRI data." *neuro.uni-jena.de*.
- 373 31 Radwan, Ahmed M., Emsell, Louise, Blommaert, Jeroen, Zhylka, Andrey, et al. (2021) "Virtual
374 brain grafting: Enabling whole brain parcellation in the presence of large lesions." *NeuroImage*,
375 229, p. 117731.
- 376 32 Nagtegaal, Steven H.J., David, Szabolcs, van der Boog, Arthur T.J., Leemans, Alexander and
377 Verhoeff, Joost J.C. (2019) "Changes in cortical thickness and volume after cranial radiation
378 treatment: A systematic review." *Radiotherapy and Oncology*, 135, pp. 33–42.
- 379 33 Winterburn, Julie L., Pruessner, Jens C., Chavez, Sofia, Schira, Mark M., et al. (2013) "A novel in
380 vivo atlas of human hippocampal subfields using high-resolution 3T magnetic resonance
381 imaging." *NeuroImage*, 74, pp. 254–265.
- 382 34 Fonov, Vladimir, Evans, Alan C., Botteron, Kelly, Almli, C. Robert, et al. (2011) "Unbiased average
383 age-appropriate atlases for pediatric studies." *NeuroImage*, 54(1), pp. 313–327.

Dose-Survival in SVZ and SGZ of patients with Glioma

- 384 35 Fonov, VS, Evans, AC, McKinstry, RC, Almlı, CR and Collins, DL (2009) “Unbiased nonlinear average
385 age-appropriate brain templates from birth to adulthood.” *NeuroImage*, 47, p. S102.
- 386 36 Atlas, ICBM (2001) “McConnell Brain Imaging Centre.” *Montréal Neurological Institute, McGill
387 University, Montréal, Canada*.
- 388 37 Cox, David R (1972) “Regression models and life-tables.” *Journal of the Royal Statistical Society:
389 Series B (Methodological)*, 34(2), pp. 187–202.
- 390 38 Kaplan, Edward L and Meier, Paul (1958) “Nonparametric estimation from incomplete
391 observations.” *Journal of the American statistical association*, 53(282), pp. 457–481.
- 392 39 Marsh, James C, Wendt, Julie A, Herskovic, Arnold M, Diaz, Aidnag, et al. (2012) “High-grade
393 glioma relationship to the neural stem cell compartment: a retrospective review of 104 cases.”
394 *International Journal of Radiation Oncology* Biology* Physics*, 82(2), pp. e159–e165.
- 395 40 Achari, R., Arunsingh, M., Badgami, R. K., Saha, A., et al. (2017) “High-dose Neural Stem Cell
396 Radiation May Not Improve Survival in Glioblastoma.” *Clinical Oncology*, 29(6), pp. 335–343.
- 397 41 Muracciole, Xavier, El-Amine, Wassim, Tabouret, Emmeline, Boucekine, Mohamed, et al. (2018)
398 “Negative survival impact of high radiation doses to neural stem cells niches in an IDH-wild-type
399 glioblastoma population.” *Frontiers in oncology*, 8, p. 426.
- 400 42 Hallaert, Giorgio, Pinson, Harry, van den Broecke, Caroline, Sweldens, Caroline, et al. (2021)
401 “Survival impact of incidental subventricular zone irradiation in IDH-wildtype glioblastoma.” *Acta
402 Oncologica*, 60(5), pp. 613–619.
- 403 43 Elicin, Olgun, Inac, Ebrar, Uzel, Esengul Kocak, Karacam, Songul and Uzel, Omer Erol (2014)
404 “Relationship between survival and increased radiation dose to subventricular zone in
405 glioblastoma is controversial.” *Journal of neuro-oncology*, 118(2), pp. 413–419.
- 406 44 Achanta, Pragathi, Capilla-Gonzalez, Vivian, Purger, David, Reyes, Juvenal, et al. (2012)
407 “Subventricular zone localized irradiation affects the generation of proliferating neural precursor
408 cells and the migration of neuroblasts.” *Stem Cells*, 30(11), pp. 2548–2560.
- 409 45 Malik, M., Akram, K.S., Joseph, D., Valiyaveetil, D. and Ahmed, S.F. (2015) “Prospective Study of
410 Irradiation of Potential Stem Cell Niches in Glioblastoma.” *International Journal of Radiation
411 Oncology* Biology* Physics*, 93(3), p. S111.
- 412 46 Fyllingen, Even Hovig, Bø, Lars Eirik, Reinertsen, Ingerid, Store Jakola, Asgeir, et al. (2021)
413 “Survival of glioblastoma in relation to tumor location: a statistical tumor atlas of a population-
414 based cohort.” *Acta Neurochirurgica*, 163, pp. 1895–1905.
- 415 47 Nourallah, B., Dignpal, R., Jena, R. and Watts, C. (2017) “Irradiating the Subventricular Zone in
416 Glioblastoma Patients: Is there a Case for a Clinical Trial?” *Clinical Oncology*, 29(1), pp. 26–33.


Dose-Survival in SVZ and SGZ of patients with Glioma

417 48 Royston, Patrick, Altman, Douglas G and Sauerbrei, Willi (2006) "Dichotomizing continuous
418 predictors in multiple regression: a bad idea." *STATISTICS IN MEDICINE Statist. Med*, 25(1), pp.
419 127–141.

420

421


Dose-Survival in SVZ and SGZ of patients with Glioma



422


423 **Figure 1.** The subventricular zone (SVZ) structure (1) and hippocampus (HPC) structure (2) including the
 424 subgranular zone (SGZ) within the dentate gyrus (DG) on T1-weighted symmetrical 0.5 mm isotropic
 425 resolution template MRI images (ICBM 2009b nonlinear symmetric). **A.** Coronal view. **B.** Axial view. **C.**
 426 Sagittal view right. **D.** Sagittal view left. **E.** 3D-model of the structures, shown from the left sagittal view.

Dose-Survival in SVZ and SGZ of patients with Glioma



427
428 **Figure 2.** Flowchart of patient selection and overview of in- and exclusion
429 criteria for patient selection. **B.** Flowchart of glioma patient selection, divided in high-grade glioma (HGG)
430 and low-grade glioma (LGG) patient cohorts. *RT* radiotherapy.

Dose-Survival in SVZ and SGZ of patients with Glioma



431

432 **Figure 3.** Overall survival (OS) curves for high- and low-dose groups, stratified by the median of the mean
 433 subventricular zone (SVZ) dose (A and C) and the median of the mean subgranular zone (SGZ) dose (B and
 434 D). **A.** OS curve of the proportion of high-grade glioma (HGG) patients relative to the median SVZ dose (p
 435 = 0.005, log-rank test). **B.** OS curve of the proportion of HGG patients relative to the median SGZ dose
 436 ($p < 0.001$, log-rank test). **C.** OS curve of the proportion of low-grade glioma (LGG) patients relative to the
 437 median SVZ dose ($p = 0.395$, log-rank test). **D.** OS curve of the proportion of LGG patients relative to the
 438 median SGZ dose ($p = 0.190$, log-rank test).

Dose-Survival in SVZ and SGZ of patients with Glioma

439 **Table 1.** Baseline patient and treatment characteristics of high-grade glioma (HGG) patients and low-grade
 440 glioma (LGG) patients.

Characteristics	HGG	LGG
Patient count (%)	226 (100)	47 (100)
Median age in years (IQR)	63 (55-70)	48 (37-59)
Sex		
Female (%)	79 (35)	16 (34)
Male (%)	147 (65)	31 (66)
Median KPS (IQR)	80 (70-80)	90 (80-90)
Total intracranial volume in cm ³ (IQR)	1540 (1424-1632)	1478 (1413-1666)
Extent of surgery		
Biopsy (%)	53 (23.5)	10 (21.3)
Partial resection (%)	117 (51.8)	31 (66)
Complete resection (%)	56 (24.8)	6 (12.8)
Chemotherapy		
No (%)	42 (18.6)	6 (12.8)
Yes (%)	184 (81.4)	41 (87.2)
Type of chemotherapy		
Temozolomide (%)	178 (96.7)	29 (70.7)
Lomustine (%)	1 (0.5)	0 (0.0)
PCV (%)	5 (2.7)	12 (29.3)
GTV – SVZ contact		
No (%)	50 (22.1)	12 (25.5)
Yes (%)	176 (77.9)	35 (74.5)
GTV – HPC contact		
No (%)	139 (61.5)	22 (46.8)
Yes (%)	87 (38.5)	25 (53.2)
MGMT methylation		
No (%)	95 (42)	3 (6.4)
Yes (%)	47 (20.8)	1 (2.1)
Unknown (%)	84 (37.2)	43 (91.5)
IDH mutation		
No (%)	208 (92)	10 (21.3)
Yes (%)	14 (6.2)	33 (70.2)
Unknown (%)	4 (1.8)	4 (8.5)
1P/19Q codeletion		
No (%)	105 (46.5)	18 (38.3)
Yes (%)	9 (4)	13 (27.7)
Unknown (%)	112 (49.6)	16 (34)

441 *IQR* Interquartile range, *PCV* Procarbazine Lomustine Vincristine, *SVZ* Subventricular zone, *HPC*
 442 Hippocampus, *MGMT* O6-methylguanine methyltransferase, *IDH* Isocitrate dehydrogenase.

Dose-Survival in SVZ and SGZ of patients with Glioma

443 **Table 2.** Cox regression analysis of subregion doses on overall survival (OS) in patients with high-grade
 444 glioma (HGG) and low-grade glioma (LGG). Analyses were performed univariate for irradiation dose only,
 445 and multivariate corrected for mentioned different covariates*.

Patient diagnosis	Subregion	Univariable		Multivariable*	
		HR (95% CI)	<i>p-value</i>	HR (95% CI)	<i>p-value</i>
High-grade glioma	HPC	1.023 (1.013-1.032)	<0.001	1.054 (1.026-1.083)	<0.001
	SGZ	1.023 (1.012-1.033)	<0.001	1.055 (1.027-1.083)	<0.001
	SVZ	1.029 (1.013-1.046)	<0.001	1.103 (1.037-1.173)	0.002
	FH	1.017 (1.004-1.030)	0.901	0.996 (0.974-1.018)	0.707
	Body	1.017 (1.004-1.030)	0.008	1.011 (0.968-1.056)	0.612
	OH	1.024 (1.013-1.034)	<0.001	1.043 (1.018-1.068)	0.001
	TH	1.024 (1.013-1.034)	<0.001	1.056 (1.025-1.088)	<0.001
*Age, Sex, KPS, total intracranial volume, MGMT, IDH, 1P/19Q deletion, CT, Surgery-extent, GTV-SVZ contact or GTV-HPC contact (For the SVZ: GTV-SVZ contact, for the SGZ: GTV-SGZ contact)					
Low-grade glioma	HPC	1.033 (0.971-1.098)	0.331	1.036 (0.947-1.132)	0.441
	SGZ	1.034 (0.974-1.098)	0.273	1.038 (0.950-1.134)	0.413
	SVZ	1.028 (0.948-1.114)	0.506	1.113 (0.949-1.305)	0.189
	FH	1.026 (0.957-1.100)	0.470	1.097 (0.982-1.226)	0.102
	Body	1.002 (0.941-1.066)	0.962	1.041 (0.941-1.139)	0.385
	OH	1.021 (0.963-1.082)	0.492	1.014 (0.920-1.117)	0.781
	TH	1.030 (0.969-1.095)	0.343	1.013 (0.935-1.097)	0.749
* Age, Sex, KPS, total intracranial volume, CT, Surgery-extent, GTV-SVZ contact or GTV-HPC contact (For the SVZ: GTV-SVZ contact, for the SGZ: GTV-SGZ contact)					

446 MGMT O6-methylguanine methyltransferase, IDH Isocitrate dehydrogenase, HPC Hippocampus, SGZ
 447 Subgranular zone, SVZ Subventricular zone, FH Frontal horn, OH Occipital horn, TH Temporal horn, HR
 448 Hazard ratio of overall survival, CI Confidence interval.

Dose-Survival in SVZ and SGZ of patients with Glioma

449 **Table 3.** Overview of the median irradiation dose received by each neurogenic subregion and Kaplan-
 450 Meier analysis of subregion doses on overall survival (OS), with median estimates for the high-grade
 451 glioma (HGG) group, and mean estimates for low-grade glioma (LGG) patients. Estimates are given in
 452 months.

Patient diagnosis	Subregion	Median dose (Gy)	Dose group	Median OS estimate (95% CI)	<i>p-value</i>
High-grade glioma	HPC	29.30	High (>29.30)	10.7 (8.6-12.7)	<0.001
			Low (<29.30)	15.7 (12.8-18.7)	
	SGZ	29.11	High (>29.11)	10.7 (8.8-12.7)	<0.001
			Low (<29.11)	15.5 (12.5-18.5)	
	SVZ	30.33	High (>30.33)	10.7 (8.6-12.8)	0.011
			Low (<30.33)	14.0 (11.6-16.3)	
	FH	34.63	High (>34.63)	13.5 (9.9-17.1)	0.830
			Low (<34.63)	12.6 (11.6-13.5)	
	Body	35.34	High (>35.34)	10.0 (8.2-11.9)	0.033
			Low (<35.34)	17.1 (11.9-16.0)	
	OH	27.92	High (>27.92)	10.0 (8.5-11.4)	<0.001
			Low (<27.92)	17.1 (14.6-19.7)	
	TH	26.95	High (>26.95)	10.8 (9.3-12.3)	<0.001
			Low (<26.95)	15.7 (10.9-20.4)	
			Mean OS estimate (95% CI)		
Low-grade glioma	HPC	29.30	High (>29.30)	54.4 (43.0-64.8)	0.314
			Low (<29.30)	60.3 (54.9-65.6)	
	SGZ	29.11	High (>29.11)	53.0 (40.8-65.3)	0.190
			Low (<29.11)	60.5 (55.4-65.6)	
	SVZ	30.33	High (>30.33)	53.8 (41.0-66.5)	0.395
			Low (<30.33)	52.5 (48.6-56.4)	
	FH	34.63	High (>34.63)	58.8 (51.9-65.7)	0.766
			Low (<34.63)	50.3 (44.3-56.4)	
	Body	35.34	High (>35.34)	57.6 (46.0-69.2)	0.988
			Low (<35.34)	51.2 (46.8-55.7)	
	OH	27.92	High (>27.92)	49.7 (36.2-63.1)	0.329
			Low (<27.92)	59.6 (54.4-64.8)	
	TH	26.95	High (>26.95)	50.2 (38.5-61.8)	0.316
			Low (<26.95)	59.5 (54.2-64.8)	

453 *HPC* Hippocampus, *SGZ* Subgranular zone, *SVZ* Subventricular zone, *FH* Frontal horn, *OH* Occipital horn,
 454 *TH* Temporal horn, *OS* overall survival, *CI* Confidence interval.